Author Archives: Yedida Y Bogachkov PhD

Wearable, AI-assisted UltiGesture May Curb Gait Freezing

An interdisciplinary research team from William and Mary University and Virginia Commonwealth University (VCU) are working on artificial intelligence programming to help develop a wearable device to treat freezing of gait (FoG), the temporary inability to move while walking, which is a motor symptom of Parkinson’s disease. “Freezing of…

Parkinson’s Foundation Opens 2022 Community Grant Applications

Applications are open for the Parkinson’s Foundation 2022 community grant cycle, with $1 million to be awarded to help fund community-based health, wellness, and education programs supporting those affected by Parkinson’s disease. Since 1957, the Foundation has invested more than $400 million toward  Parkinson’s research and clinical care.

STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s

Gain Therapeutics announced that preclinical studies with two of its compounds, GT-02287 and GT-02329, showed they could reduce the alpha-synuclein aggregates that characterize Parkinson’s and increase glucocerebrosidase protein levels in cell models of Parkinson’s and Gaucher disease. GT-02287 and GT-02329 are known as STARs, which stands for structurally targeted…

2 Northwestern Researchers Awarded $17.9M in ASAP Grants

Scientists from Northwestern University will use two grants — totaling $17.9 million — from the Aligning Science Across Parkinson’s (ASAP) initiative to study alterations in the brain that contribute to the development of Parkinson’s disease. Their research focuses on brain circuits, the specific populations of interconnected brain cells…

$1.1M NIH Grant Will Further AI-powered Research Analysis

A team of scientists from the University of Florida (UF) will use a $1.1 million grant to further their work on the use of artificial intelligence- or AI-powered medical research for predicting and diagnosing Parkinson’s disease while maintaining patient privacy. This grant, from the National Institutes for Health (NIH),…

FDA Approval Sought to Begin Phase 2 Trial of KM-819

FAScinate Therapeutics has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KM-819 as a potential therapy for Parkinson’s disease, the company announced in a press release. Parkinson’s disease is characterized by the death and dysfunction…

Mutation Affecting Myelin Protein May Raise Parkinson’s Risk

A specific genetic variant, or mutation, that is associated with an increased risk of developing amyotrophic lateral sclerosis (ALS) may also raise a person’s risk of Parkinson’s disease, a study reported. Shared features of both these neurodegenerative disorders include causative processes and “genetic backgrounds,” the researchers noted, suggesting that a mutation affecting…

JUBIwatch Device Targets Medication Adherence

Jubilee BioTech has developed JUBIwatch, a new device intended to improve patients’ medication adherence — taking medicines at the right time with the right dose. Under development by the startup South Korean company for the past two years, JUBIwatch is a smart watch and medication management platform that uses microneedles…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums